key: cord-0920563-whkda964 authors: DeFilippis, Ersilia M; Moayedi, Yasbanoo; Reza, Nosheen title: Representation of Women Physicians in Heart Failure Clinical Practice date: 2021-03-31 journal: Card Fail Rev DOI: 10.15420/cfr.2020.31 sha: 87737d47a9bf75e0719c26763bf5ec2a3ba95b1b doc_id: 920563 cord_uid: whkda964 Women have been integral in the development of advanced heart failure (HF) and transplantation as a clinical subspecialty of cardiovascular medicine. However, women remain underrepresented in leadership positions, senior academic ranks and as researchers in HF. In recent years, there have been accelerating efforts to examine sex differences in the clinical and research domains of HF. The purpose of this review is to discuss the representation of women in HF training programmes and clinical practice, the demographics of HF clinicians compared with other cardiology subspecialties, the persistent sex disparities in HF practice and research environments and potential strategies to promote equity and inclusion for women in the field. suggesting that cardiac transplantation could prolong survival and return patients to improved functional status. 10 Dr Hunt was also a leader in major cardiovascular professional societies. She was the Chair of the inaugural ACC/American Heart Association (AHA) Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult, published in 2001, and served as President of the International Society for Heart and Lung Transplantation from 1995 to 1996. 9 Equally important in the field of advanced HF and cardiac transplantation in the 1980s was another trailblazing female clinical investigator, Dr Hannah Valantine. At Stanford, she led innovative research in applying Doppler and M-mode echocardiography to the detection of allograft rejection. 11 She was mentored by Dr Hunt, and the two women closely collaborated to advance the science of long-term immunosuppression, cardiac allograft vasculopathy and more. [12] [13] [14] [15] Dr Valantine was promoted to full professor at Stanford in 2000 and became the inaugural Senior Associate Dean for Diversity and Leadership in 2004. 16 She became nationally recognised for her revolutionary success in promoting diversity in the workforce, and was recruited to the National Institutes of Health (NIH) in 2014 as the inaugural Chief Officer for Scientific Workforce Diversity and as a tenured investigator in the National Heart, Lung, and Blood Institute. There, Dr Valantine established novel programmes, such as the Distinguished Scholars Program and the NIH Equity Committee that served to dramatically increase the representation of women, and of African-American/black and Hispanic tenure-track principal investigators, and of women in NIH leadership positions. In addition to each of their remarkable professional legacies, both Dr Hunt and Dr Valantine have inspired generations of clinicians and investigators, many of whom have been women who have subsequently led the field of HF and cardiac transplantation as it continued to evolve in the 1990s. In 1995, Dr Hunt and others published recommendations on training HF and transplantation in the Journal of the American College of Cardiology. As part of this first Core Cardiology Training Symposium, she and other taskforce members created perhaps the earliest call for a subspecialty in HF and transplantation. 17 The taskforce encouraged such training to occur at centres with established programmes in clinical cardiac transplantation with at least 20 transplant procedures annually. Members emphasised that programmes should be staffed by board-certified cardiologists with expertise in cardiac transplantation, and should require 1 year of training in all phases of pre-and post-transplant clinical management. 17 Beginning in 2004, the Heart Failure Society of America (HFSA) built on Dr Hunt's efforts from the prior decade and began to advocate for the need for a subspecialty focused on advanced HF. 18 The HFSA also encouraged other professional societies, such as the ACC, to support its advocacy efforts. The society posited that, in light of an expanding population of individuals with HF, specialists would be uniquely positioned to provide excellence in care for complex patients. subspecialty of Advanced Heart Failure and Transplant Cardiology and a pathway for board certification. 19 Since that time, the field of advanced HF has grown significantly and has become a subspecialty that is attractive to women. Dr Hunt postulated that women may be more highly represented in HF for a few reasons, including the enduring presence of women role models and mentors and support for the inclusion of women from the time of the field's inception. 20 It is perhaps the only subspecialty within cardiology that was largely spurred by women and one in which women have played key roles in its development ( Figure 1 ). Dr Hunt also speculated that women have been successful in HF careers because of their proclivity for collaborative work, a particularly important skill for a multidisciplinary field, such as advanced HF and cardiac transplantation. The field developed with the partnership and leadership of women, and therefore, was not perceived as being "exclusive to male colleagues". 20 Dr Hunt, Dr Valantine and many other renowned and highly accomplished women have advanced the field and served as role models, mentors and sponsors for both women and men. In the US, there are currently 80 accredited advanced HF programmes in 35 states. The ABIM regularly collects data by sex of first-year fellows in Accreditation Council for Graduate Medical Education-accredited training programmes. From 2011 to 2019, the percentage of women in general cardiology fellowship training programmes has increased from 21% to 25%. For women in AHFTC programmes, the percentage is between 26% and 36% ( Figure 2 ). This is significantly higher than that of women in more procedural subspecialties, such as clinical cardiac electrophysiology and interventional cardiology, similar to the trends observed in the demographics of board-certified cardiologists. 21 As of December 2016, there were 939 cardiologists who were ABIM board certified in AHFTC; of these, 239 (25.5%) were women. 1 22 At the ESC Heart Failure Congress in recent years, the proportion of women attendees has been consistently higher than that of men among the younger age groups. Similar trends have also been seen in the distribution of men and women taking the Heart Failure Association Certification exam in Europe, suggesting increasing interest in HF as a subspecialty among young women cardiologists. 22 Within the HFSA, data show that 59% of active members, as of November 2020, were women (J Leonard, Personal Communication, 20 November 2020). However, only 29% of the women members are physicians and 9% are trainees. Of the women members, 32% are early career (0-5 years after training), 26% mid-career and 36% established career (6% did not indicate a career level). Despite the relatively higher proportions of women in HF, their representation in professional society leadership positions remains low. The AHA was founded in 1924, and Dr Helen Taussig served as its first woman president in 1965. Among subsequent women AHA presidents was Dr Mariell Jessup (President 2013-2014), who was also instrumental in achieving formal recognition for AHFTC as a certified subspecialty. 23 Since the founding of the ACC in 1949, there have been 68 organisational presidents; four of these have been women. 27 Of these women, one, Dr Mary Norine Walsh (President 2017-2018), practices in advanced HF and cardiac transplantation. In Canada, HF clinician, Dr Heather Ross, has served as President of both the Canadian Society of Transplantation (2004) (2005) and the Canadian Cardiovascular Society (2015-2016). 28, 29 The Heart Failure Association of the ESC was launched in 2004 and has not been led by a woman to date. 30 Since 1996, there have been 15 presidents of the HFSA. The first woman HFSA President, Dr JoAnn Lindenfeld, was inaugurated in 2014, nearly 10 years after the organisation's founding. Dr Biykem Bozkurt (President 2019-2020) and Dr Nancy Albert (President 2020-2021) are the organisation's second and third women presidents, respectively. Similarly, from 1981 to 2020, there have been 37 presidents of the International Society for Heart and Lung Transplantation. Of these, only five (13.5%) have been women. 31 One of these five women, Dr Maryl R Johnson, also served as President of the American Society of Transplantation (2010-2011). 32 Despite the demographics of women in HF clinical practice, women still perceive sex-based imbalances with regard to salary, leadership positions and academic promotions. 8 In 2019, Moayedi and colleagues surveyed 236 international HF cardiologists to determine factors that influenced their career choices. 8 Among both women and men, the three most important factors attracting respondents to careers in HF cardiology included patient complexity and continuity of care, clinical diversity and evolving technology. There were no differences in rank order by sex of the respondent. 8 Participants emphasised an increased need for sponsorship, increased support for maternity leave and income transparency to attract and maintain women in HF. 8 Regarding academic rank, more men than women had achieved the rank of professor with no differences at the assistant or associate professor levels. 33 While this is a potentially biased sample of those who responded to a voluntary survey, these findings are consistent with disparities observed in academic medicine, at least in the US, more broadly. 6 Women also remain underrepresented as clinical trialists in cardiology and in HF. We previously reviewed the publications referenced in Class I recommendations in both US and European guidelines for management of HF, as well as all HF clinical trials published from 2001 to 2016 with more than 400 participants. 34 The overall proportions of women as first authors in the referenced publications in the US and European guidelines were 18% and 16%, respectively, and, as senior authors, were 13% and 12%. Of the examined clinical trials, 16% of publications had a woman as first or senior author, and the median number of women authors per trial was one. Overall proportions of women as first or senior authors of HF clinical trial publications did not increase over the 15-year study period. Industry-funded trials had fewer women authors per trial; it has been previously demonstrated that women receive fewer total dollars from financial relationships with pharmaceutical and device companies compared with men. 35 In addition, we found an association between the number of women authors of HF clinical trials with the enrolment of women participants. 34 Outreach initiatives and dedicated efforts are needed to increase support for women HF researchers and site investigators, as well as collaborations with industry, which may also help stimulate increased representation of women in HF clinical trials. Another recent systematic review of 403 HF randomised controlled trials published in high impact journals from 2000 to 2019 found that women only represented 15.6% of lead authors, 12.9% of senior authors and 11.4% of corresponding authors. 36 Notably, there were no significant changes in the representation of women as lead authors over time. Women were less likely to be lead authors in multicentre trials, those conducted in North America or Europe or had men as senior authors. 36 These data highlight the critical need to sustainably increase and advance diversity, equity and inclusion in the field of AHFTC. In 2019, Dr Nancy Sweitzer proposed a valuable multipronged thematic framework to address these issues. 33 AHFTC can be an emotionally demanding specialty that frequently encompasses advanced and critical illness, death and dying. This can be burdensome to both men and women, but can be exacerbated by lack of institutional support or mentorship, which may disproportionately affect women. As Sweitzer writes: "workplace discrimination is not merely an issue of numbers", and culture change must be implemented to reduce workplace harassment and microaggressions. 33 While equal hiring, remuneration and representation of women in HF is paramount, we also need to strive for policies that lead to lasting behavioural, cultural and structural changes. These actions are especially important to advance women's research careers and include the diversification of manuscript and grant reviewers, journal editorial boards and steering and leadership committees. 37 Equally important strategies include the implementation of family-friendly policies, flexible work structures and support for adequate and equitable parental leaves. Additionally, sponsorship is necessary for creating diverse professional networks and workplace paradigms that value and reward mutual respect, teamwork and collaboration (Figure 3 ). Since its inception, the field of advanced HF and cardiac transplantation has had pioneering women cardiologists at its helm. These women have helped to define the subspecialty and served as role models, mentors and sponsors for many generations of female and male HF physicians. The relatively increased representation of women in HF training programmes and clinical practice may uniquely position us to provide guidance to other subspecialties with respect to the recruitment and promotion of women. However, the small numbers of women in leadership positions in clinical practice, academics and research, and enduring disparities, highlight that many opportunities for improvement remain, and undoubtedly women in HF will continue to lead the way. Current demographic status of cardiologists in the United States Where are the women in academic cardiology? Diversity matters Women in cardiology: introspection into the under-representation Sex differences in faculty rank among academic cardiologists in the United States Women physicians and promotion in academic medicine Changes in the professional lives of cardiologists over 2 decades Perceived generational, geographic, and sex-based differences in choosing a career in advanced heart failure: an international survey Women as leaders in cardiovascular medicine Does cardiac transplantation prolong life and improve its quality? An updated report Changes in Doppler echocardiographic indexes of left ventricular function as potential markers of acute cardiac rejection Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection Cardiac allograft vascular disease. Relationship to microvascular cell surface markers and inflammatory cell phenotypes on endomyocardial biopsy Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens Gene-expression profiling for rejection surveillance after cardiac transplantation Guidelines for training in adult cardiovascular medicine. Core Cardiology Training Symposium (COCATS) Heart failure training: a call for an integrative, patient-focused approach to an emerging cardiology subspecialty Advanced heart failure and transplant cardiology: a subspecialty is born Women Leaders in cardiac transplantation: a historical and personal perspective Percentage of firstyear fellows by gender and type of medical school attended Jessup: shaping a subspecialty focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Heart-Failure-Association-of-the-ESC-(HFA)/About/Board The International Society for Heart and Lung Transplantation. Past Presidents. 2020 Choosing a career in heart failure Representation of women authors in international heart failure guidelines and contemporary clinical trials Gender differences in physicians' financial ties to industry: a study of national disclosure data Characteristics of heart failure trials associated with under-representation of women as lead authors The cascading effects of COVID-19 on women in cardiology Acknowledgement: The authors acknowledge Jaime Abreu, Ana Lybecker and Jeanne Leonard of the Heart Failure Society of America for their assistance in obtaining the data reported in this manuscript.